STS Intermacs 2024年度报告:聚焦年轻患者结局
该报告基于2014至2024年29,634例连续流左心室辅助装置(LVAD)数据,显示全磁悬浮装置者1年与5年生存率显著高于非磁悬浮装置者(85.7% vs 78.4%;59.7% vs 43.7%)。年轻(<50岁)患者生存更优(1年91.6%,5年72.6%)且不良事件更少,提示可考虑延长LVAD支持后再行心脏移植。
要点
- 全磁悬浮LVAD者1年生存85.7%、5年59.7%,显著优于非磁悬浮装置。
- 5年无消化道出血72.6%、无装置故障82.9%、无卒中86.7%。
- 年轻患者1年生存91.6%、5年72.6%,不良事件更少。
核心结论
- 全磁悬浮LVAD时代生存持续改善,年轻患者结局更优且不良事件更少。
- 年轻患者或可考虑延长LVAD支持后再行心脏移植以延长生存。
研究设计与样本
- STS Intermacs第15次年度报告,纳入2014至2024年29,634例连续流LVAD。
- 重点分析年轻(<50岁)亚组结局。
主要发现
- 全磁悬浮装置者1年生存85.7% vs 非磁悬浮78.4%,5年59.7% vs 43.7%。
- 全磁悬浮装置者5年无消化道出血72.6%、无装置故障82.9%、无卒中86.7%。
- 年轻患者1年生存91.6%、5年生存72.6%,不良事件少于年长患者。
- 年轻患者对性别、种族、族裔及心理社会指标耐受性更好。
临床怎么用
- 年轻晚期心衰患者可考虑LVAD作为移植前延长支持策略。
- 全磁悬浮装置可能扩大LVAD适用人群并优化供体分配。
局限性
- 报告为初步数据,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 15th Annual Report from The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support includes 29,634 continuous-flow left ventricular assist devices from the 10-year period between 2014 and 2024. The outcomes reported here demonstrate continued improved survival in the current era of fully magnetically levitated devices, with a significantly higher 1-year (85.7% vs 78.4%) and 5-year (59.7% vs 43.7%) survival than those receiving non-magnetically levitated devices. Magnetically levitated device recipients are experiencing a lower incidence of adverse events, including freedom from gastrointestinal bleeding (72.6%), device malfunction (82.9%), and stroke (86.7%) at 5 years. Additionally, a focus on a subgroup of patients younger than 50 years of age has demonstrated both superior outcomes in survival (91.6% survival at 1 year and 72.6% survival at 5 years) and decreased incidence of adverse events compared with older recipients. This younger cohort also demonstrated more tolerance to the characteristics of sex, race, ethnicity, and psychosocial indicators that are associated with worse outcomes after heart transplantation. Based upon these data, a potential net prolongation of life may be realized by considering prolonged left ventricular assist device support prior to heart transplantation in this population. These analyses provide preliminary data that could positively influence adoption of left ventricular assist device technology in groups previously not seen as candidates for this therapy, while providing a more responsible donor allocation strategy for advanced heart failure patients.
引用
- Meyer DM, Nayak A, Wood KL, et al. The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. Ann Thorac Surg. 2024. PMID: 39442906. doi:10.1016/j.athoracsur.2024.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。